Senior/Medical Director (Autoimmune experience) at Vor Bio

Boston, Massachusetts, United States

Apply Now

Not SpecifiedCompensation

Senior (5 to 8 years), Expert & Leadership (9+ years)Experience Level

Full TimeJob Type

UnknownVisa

Biotechnology, PharmaceuticalsIndustries

Requirements

MD degree required
Board certification in Rheumatology or Neurology is highly desired
A minimum of 5 years of clinical research experience
Clinical trial experience in autoimmune indications in an industry setting (e.g., pharmaceutical, biotech, or CRO) is strongly preferred
Must be motivated, proactive, and have excellent communication skills

Responsibilities

Provide medical and scientific leadership to clinical development strategies and protocol development
Lead execution of phase 2 and 3 clinical trials in collaboration with cross functional team including clinical operations, regulatory, pharmacovigilance, CMC, and other relevant functions
Ensure subject eligibility and monitor safety of subjects
Engage investigators and provide guidance on protocol design, procedures and patient recruitment and retention
Lead clinical portion of IND, IBs, CTAs, BLAs and other regulatory submissions
Authorship of abstracts, manuscripts for publication based on clinical trial results
Present data and scientific information to the organization at all levels
Building credible relationships with key opinion leaders and external alliances when relevant
May involve in business development opportunities

Skills

Autoimmune Diseases

Clinical Development

Phase 2 Trials

Phase 3 Trials

Protocol Development

Regulatory Submissions

IND

CTA

BLA

Pharmacovigilance

CMC

Patient Recruitment

Manuscript Writing

Vor Bio

Develops targeted therapies for blood cancers

About Vor Bio

Vor Biopharma focuses on developing treatments for blood cancers, particularly Acute Myeloid Leukemia (AML). Their approach is designed to protect healthy cells while specifically targeting and eliminating cancerous cells. This method aims to improve the effectiveness of blood cancer treatments. Vor Biopharma serves patients with blood cancers, their caregivers, and medical professionals in hospitals and oncology centers. What sets Vor Biopharma apart from competitors is their strong emphasis on research and development, investing significantly in scientific research to create a proprietary platform and pipeline of therapies. They generate revenue through partnerships with other pharmaceutical companies and licensing agreements, with the goal of commercializing their therapies after obtaining regulatory approval. The company's mission is to transform the treatment landscape for blood cancers by providing innovative therapies that prioritize patient safety and efficacy.

Cambridge, MassachusettsHeadquarters

2015Year Founded

$147.9MTotal Funding

IPOCompany Stage

Biotechnology, HealthcareIndustries

51-200Employees

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Paid Vacation

Parental Leave

401(k) Retirement Plan

401(k) Company Match

Commuter Benefits

Risks

Significant YTD price decline of -62.76% may affect investor confidence.

Key clinical trial data updates are not expected until 2025, causing uncertainty.

Increased competition from companies like Editas Medicine poses potential conflicts.

Differentiation

Vor Bio focuses on protecting healthy cells while targeting cancerous ones.

The company specializes in innovative treatments for blood cancers like AML.

Vor Bio's approach aligns with the rise of personalized medicine.

Upsides

Recent $55.6M funding supports clinical trials and extends cash runway to 2025.

FDA's acceptance of gene therapies may ease approval for Vor Bio's treatments.

Advancements in CRISPR technology enhance precision of Vor Bio's gene editing.

Land your dream remote job 3x faster with AI

Try Jobo Free